🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Engineered natural killer cells for cancer therapy

Cancer Cell(2025)10.1016/j.ccell.2025.09.013Source: DataRank Database

Engineered natural killer cells for cancer therapy is a research paper published in Cancer Cell (2025). On theSindex it has a DataRank of 0. It has been cited 39 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access39 citations

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 15.50)OA: hybridTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Katayoun Rezvani ORCID,Alexander Biederstädt ORCID

Live enrichment

PubMed:41135520 PMC:PMC12631954 OpenAlex:https://openalex.org/W4415478993

National Institutes of Health National Cancer Institute

Grant: 1 R01 CA211044-01

National Institutes of Health National Cancer Institute

Grant: 1 R01CA280827-01

National Institutes of Health National Cancer Institute

Grant: 1 R01CA288617-01

National Institutes of Health National Cancer Institute

Grant: P50CA127001

National Institutes of Health National Cancer Institute

Grant: P30 CA016672

National Institutes of Health National Cancer Institute

Grant: 5P50CA281701-02

Stand up to Cancer

Grant: SU2C-AACR-DT-29-19

NCI NIH HHS

Grant: P01 CA148600

NCI NIH HHS

Grant: P50 CA100632

NCI NIH HHS

Grant: P50 CA281701

NCI NIH HHS

Grant: R01 CA288617

NCI NIH HHS

Grant: R01 CA211044

NCI NIH HHS

Grant: R01 CA280827

National Institutes of Health

Cockrell Foundation

Marcus Foundation

Tanoto Foundation

University of Texas MD Anderson Cancer Center

FWCI

15.50

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.ccell.2025.09.013

publisherhttps://doi.org/10.1016/j.ccell.2025.09.013

publisherhttps://api.elsevier.com/content/article/PII:S1535610825004052?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610825004052?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41135520

Fields of Study

Immune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell Immunology

MeSH Terms

Gene EditingReceptors, Chimeric AntigenAnimalsHumansImmunotherapyKiller Cells, NaturalNeoplasmsImmunotherapy, AdoptiveTumor MicroenvironmentCell Engineering

Keywords

Chimeric antigen receptorImmunotherapyCancer immunotherapyClinical trialCell therapyGenetic enhancementCancerTranslational researchEffectorNatural killer cellsCellular engineeringTumor MicroenvironmentSolid TumorsAdoptive Cell TherapyPrecision Gene EditingCrispr ScreeningPerturbomics